EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

Irfan Cicin iD, Nuri Karadurmus iD, Ahmet Bilici iD, Taha Bahsi iD, Mehmet Ali Sendur iD, Umut Demirci iD, Sema Sezgin Goksu iD, Ozlem Er iD, Atil Bisgin iD, Ozge Fulya Ozturk Saglam iD, Birkan Aver iD, Saadettin Kilickap iD

Future Oncology · 2024

DOI: 10.2217/fon-2023-0518 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Oncology, 2024. Verfasst von Irfan Cicin und 11 weiteren Autor:innen. Beteiligte Einrichtung: İstinye University, Department of Internal Medicine, Division of Medical Oncology, Istanbul, Türkiye. Hauptthemen laut MEDLINE: BRCA1 Protein, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer pharmaceuticals, Türkiye.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to current evidence, testing for germline BRCA pathogenic variants in newly diagnosed breast cancer (BC) patients has the potential to reduce the burden of the disease through targeted therapies and secondary prevention. A personalized approach to testing can lead to improved individual outcomes for patients. Despite the proven clinical utility and therapeutic impact of BRCA1/2 tests in shaping therapy for metastatic BC, awareness and access to these tests are limited in many developing countries, including Türkiye. This limitation impacts the healthcare economy as delayed or missed interventions can lead to increased long-term costs. The limited access is mainly due to fear of stigmatization among patients, country-specific legislation and costs, a lack of awareness, vagueness surrounding the tests and access restrictions. This review offers a perspective for policymakers and healthcare providers in Türkiye to establish pathways that integrate the patient experience into comprehensive care pathways and national cancer control plans. Recent studies show that testing for a specific gene change in people newly diagnosed with breast cancer can help reduce the impact the disease has on their life as they can be given special treatments. When tests are tailored to each person, they can get better results. However, in many countries, including Türkiye, not many people know about or can get these tests. This is because of concerns about being judged, rules in the country, the cost, confusion about the tests and limited access. Not having these tests can make healthcare more expensive in the long run. This article suggests ways for Türkiye's leaders and health workers to make these tests a regular part of cancer care and planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA1 ProteinBreast NeoplasmsHumansFemaleTurkeyBRCA2 ProteinGenetic TestingGenetic CounselingCounseling

Stichwörter der Autor:innen

BRCA pathogenic variantbreast cancergenetic testinghealthcare economyimproved individual outcomespersonal approach

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • İstinye University, Department of Internal Medicine, Division of Medical Oncology, Istanbul, Türkiye.
  • Gulhane Research & Training Hospital, Department of Internal Medicine, Division of Medical Oncology, Ankara, Türkiye.
  • Medipol University, Department of Internal Medicine, Division of Medical Oncology, Istanbul, Türkiye.
  • Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Türkiye.
  • Ankara Yıldırım Beyazıt University, Department of Internal Medicine, Division of Medical Oncology, Ankara, Türkiye.
  • Memorial Ankara Hospital, Department of Internal Medicine, Division of Medical Oncology, Ankara, Türkiye.

ORCID-Profile: Irfan Cicin, Nuri Karadurmus, Ahmet Bilici, Taha Bahsi, Mehmet Ali Sendur, Umut Demirci, Sema Sezgin Goksu, Ozlem Er, Atil Bisgin, Ozge Fulya Ozturk Saglam, Birkan Aver, Saadettin Kilickap

Förderung

  • Pfizer pharmaceuticals, Türkiye

Zitieren

APA

Cicin, I., Karadurmus, N., Bilici, A., Bahsi, T., Sendur, M. A., Demirci, U., Goksu, S. S., Er, O., Bisgin, A., Ozturk Saglam, O. F., Aver, B., & Kilickap, S. (2024). Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye. Future Oncology. https://doi.org/10.2217/fon-2023-0518

Vancouver

Cicin I, Karadurmus N, Bilici A, Bahsi T, Sendur MA, Demirci U, et al. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye. Future Oncology. 2024. doi:10.2217/fon-2023-0518

BibTeX
@article{Cicin2024,
  author = {Cicin, Irfan and Karadurmus, Nuri and Bilici, Ahmet and Bahsi, Taha and Sendur, Mehmet Ali and Demirci, Umut and Goksu, Sema Sezgin and Er, Ozlem and Bisgin, Atil and Ozturk Saglam, Ozge Fulya and Aver, Birkan and Kilickap, Saadettin},
  title = {Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-0518}
}
Kostenlos starten →